Syngene International appoints five new members to Executive Committee
Bengaluru: Syngene International Limited has announced key changes in its senior management, inducting five leaders into its Executive Committee with effect from August 20, 2025.
The company has appointed Ajay Tandon, Head of Strategy and Corporate Development; Gaurav Kushwaha, Chief Technology Officer; Dr. Mrinal Kammili, Head of Translational and Clinical Research; Dr. Subhendu Kumar, Head of Chemistry; and Dr. Priyaranjan Pattanaik, Head of Biology, as members of the Executive Committee.
Ajay Tandon brings more than 30 years of leadership experience spanning life sciences, private equity, and banking. He focuses on envisioning business potential, strategic planning, and managing execution. Driven by a passion for innovation and growth, he thrives on engaging with people, ideas, and challenges. Renowned for his integrity and perseverance, Ajay cultivates enduring, trust-based relationships.
Gaurav Kushwaha is a digital transformation leader with more than twenty years of experience across telecom, banking, Defense, pharma, chemicals, and manufacturing. He specializes in designing and implementing IT and digital strategies that drive EBITDA impact, reduce costs, and enhance business processes, earning over 20 global recognitions, including DEMING and Lighthouse awards.
Dr. Mrinal Kammili is a senior healthcare professional with more than 27 years of experience across healthcare, pharmaceuticals, clinical research, and life sciences. As a medical doctor, PhD holder, and AHAqualified intensivist, he blends clinical expertise with strong leadership to foster organizational growth and deliver client-centric value.
Dr. Subhendu Kumar is an experienced medicinal chemist specializing in GPCR and oncology drug discovery. He has successfully led CRO projects involving more than 20 chemists to deliver leadoptimized candidates and possesses extensive experience in library synthesis of over 1,000 compounds. His expertise covers organic and medicinal chemistry, biology, ADMET, and drug discovery, supported by strong communication skills and collaborative leadership.
Dr. Priyaranjan Pattanaik, Ph.D., is a seasoned scientist and business leader with over 23 years of experience in pharmaceuticals and biotech within the CRO/CDMO space. With deep expertise in biotherapeutics— including antibodies, bispecifics, ADCs, peptides, proteins, and cell/gene therapies—he has led programs from discovery through clinical development. A passionate mentor and advocate for innovation, he brings strong scientific leadership and talent development skills.
Next Story